Baxter International Inc (BAX.xnys) is a global health care company with headquarters in Illinois, America. Baxter Inc. operates two businesses: BioScience and Medical Products to treat kidney disease and other chronic and acute medical conditions. Both businesses produce recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders, inhalational anaesthetics and products to treat end-stage kidney disease or irreversible kidney failure, including peritoneal dialysis and hemodialysis. The company has 75 office locations across 40 countries and employs 48,000 people (2017). Baxter International Inc. (BAX.xnys) is listed on the New York Stock Exchange (NYSE), has a market cap of $38.07B (USD) as of November 2021 and an $11.67B (USD) 2020 annual revenue. Baxter is the parent company of 47 subsidiaries, including GAMBRO, CHEETAH Medical Inc., Baxter S.p.A, APATECH Limited, Synovis Micro Companies Alliance Inc. The company announced the expansion of $100M (USD) of its sterile fill/finish manufacturing facility which is operated by BioPharma Solutions (BPS), located in Halle, Germany. Baxter's business unit BioPharma specialises in partnering with leading pharmaceutical and biotech companies to develop and contract drug products for parenteral pharmaceuticals. The construction of the new manufacturing building is expected to begin in 2022 and be completed in 2024.
Baxter International Inc (BAX)
Get Baxter International Inc (BAX) share price analysis and insights to refine your trading decisions. Stay updated with FP Markets Rwanda.